Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT).

PubWeight™: 0.87‹?›

🔗 View Article (PMID 25064723)

Published in Ophthalmology on July 23, 2014

Authors

Joo Yong Lee1, Francisco A Folgar2, Maureen G Maguire3, Gui-shuang Ying3, Cynthia A Toth2, Daniel F Martin4, Glenn J Jaffe5, CATT Research Group

Author Affiliations

1: Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina; Department of Ophthalmology, Asan Medical Center, University of Ulsan, Seoul, Korea.
2: Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
3: Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
4: Department of Ophthalmology, Cleveland Clinic, Cleveland, Ohio.
5: Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina. Electronic address: glenn.jaffe@duke.edu.

Associated clinical trials:

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial | NCT00593450

Articles by these authors

Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 3.85

Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.73

Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70

Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography. Ophthalmology (2013) 1.35

Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol (2014) 1.20

Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.07

Ocular safety of recreational lasers. JAMA Ophthalmol (2014) 1.06

Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology (2014) 0.89

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.88

Drusen Volume and Retinal Pigment Epithelium Abnormal Thinning Volume Predict 2-Year Progression of Age-Related Macular Degeneration. Ophthalmology (2015) 0.87

Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2015) 0.86

Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 0.84

Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol (2014) 0.83

Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 0.83

Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol (2014) 0.82

Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology (2015) 0.82

VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. Ophthalmology (2015) 0.79

Endothelial PAS domain-containing protein 1 (EPAS1) gene polymorphisms and response to anti-VEGF therapy in the comparison of AMD treatments trials (CATT). Ophthalmology (2014) 0.78

Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol (2016) 0.76

Author reply: To PMID 24084496. Ophthalmology (2014) 0.75

Author reply: To PMID 23337555. Ophthalmology (2014) 0.75

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology (2020) 0.75

Comparison of cycloplegic refraction between Grand Seiko autorefractor and Retinomax autorefractor in the Vision in Preschoolers-Hyperopia in Preschoolers (VIP-HIP) Study. J AAPOS (2017) 0.75

A Comparative Study of Rebound Tonometry With Tonopen and Goldmann Applanation Tonometry Following Vitreoretinal Surgery. Am J Ophthalmol (2015) 0.75

Comparison of Visual Outcomes in Coats' Disease: A 20-Year Experience. Ophthalmology (2017) 0.75

Association between pseudodrusen and delayed patchy choroidal filling in the comparison of age-related macular degeneration treatments trials. Acta Ophthalmol (2017) 0.75